Eagle Asset Management Inc. lessened its stake in Catalent Inc (NYSE:CTLT) by 30.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 411,309 shares of the company’s stock after selling 183,916 shares during the period. Eagle Asset Management Inc. owned 0.28% of Catalent worth $19,602,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of the business. BlackRock Inc. grew its holdings in Catalent by 2.8% during the 2nd quarter. BlackRock Inc. now owns 14,307,589 shares of the company’s stock worth $775,615,000 after acquiring an additional 388,615 shares in the last quarter. Highline Capital Management L.P. bought a new stake in shares of Catalent in the 2nd quarter valued at about $111,494,000. Invesco Ltd. boosted its holdings in shares of Catalent by 11.9% in the 2nd quarter. Invesco Ltd. now owns 1,774,766 shares of the company’s stock valued at $96,210,000 after buying an additional 188,998 shares in the last quarter. Viking Global Investors LP boosted its holdings in shares of Catalent by 50.5% in the 2nd quarter. Viking Global Investors LP now owns 1,595,579 shares of the company’s stock valued at $86,496,000 after buying an additional 535,066 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Catalent by 2.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,553,474 shares of the company’s stock valued at $84,214,000 after buying an additional 32,691 shares in the last quarter.
In other Catalent news, CEO John R. Chiminski sold 97,043 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $48.84, for a total transaction of $4,739,580.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gregory T. Lucier purchased 2,000 shares of Catalent stock in a transaction on Monday, September 9th. The shares were acquired at an average cost of $51.64 per share, with a total value of $103,280.00. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company’s stock.
CTLT stock traded up $0.27 during trading on Friday, reaching $49.52. The company had a trading volume of 467,188 shares, compared to its average volume of 806,017. The firm has a 50-day simple moving average of $49.09 and a 200-day simple moving average of $50.57. The company has a market cap of $7.38 billion, a price-to-earnings ratio of 30.57, a price-to-earnings-growth ratio of 2.47 and a beta of 1.69. The company has a debt-to-equity ratio of 2.74, a quick ratio of 1.70 and a current ratio of 2.06. Catalent Inc has a twelve month low of $29.23 and a twelve month high of $58.38.
Catalent (NYSE:CTLT) last released its earnings results on Tuesday, November 5th. The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.07. The company had revenue of $664.70 million during the quarter, compared to analysts’ expectations of $634.87 million. Catalent had a net margin of 5.77% and a return on equity of 16.87%. Catalent’s revenue for the quarter was up 20.5% on a year-over-year basis. During the same period last year, the business earned $0.28 EPS. Sell-side analysts expect that Catalent Inc will post 1.81 earnings per share for the current year.
CTLT has been the subject of a number of recent analyst reports. UBS Group lifted their target price on shares of Catalent to $64.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Robert W. Baird lifted their target price on shares of Catalent from $50.00 to $60.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 28th. ValuEngine cut shares of Catalent from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Stephens initiated coverage on shares of Catalent in a research note on Thursday, October 17th. They issued an “overweight” rating and a $56.00 target price for the company. Finally, Zacks Investment Research cut shares of Catalent from a “buy” rating to a “hold” rating in a research note on Tuesday, October 29th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Catalent has an average rating of “Buy” and a consensus target price of $56.25.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Read More: Blue-Chip Stocks
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.